Morgan Stanley Initiates Coverage On Belite Bio with Overweight Rating, Announces Price Target of $191
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
Morgan Stanley analyst Judah Frommer initiates coverage on Belite Bio (NASDAQ:BLTE) with a Overweight rating and announces Price Target of $191.
Morgan Stanley analyst Judah Frommer initiates coverage on Belite Bio (NASDAQ:BLTE) with a Overweight rating and announces Price Target of $191.